Evidence map›Paper›PMID 30402987›Full record

Trial reportThe European journal of neuroscience2019

Naltrexone differentially modulates the neural correlates of motor impulse control in abstinent alcohol-dependent and polysubstance-dependent individuals.

Liam J Nestor, Louise M Paterson, Anna Murphy, John McGonigle, Csaba Orban, Laurence Reed, Eleanor Taylor, Remy Flechais, Dana Smith, Edward T Bullmore and 10 more

Open access · hybridAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in The European journal of neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 1 country.

Liam J NestorNeuropsychopharmacology Unit, Centre for Psychiatry, Imperial College London, London, UK.ORCID 0000-0002-8854-9908
Louise M PatersonNeuropsychopharmacology Unit, Centre for Psychiatry, Imperial College London, London, UK.
Anna MurphyNeuroscience and Psychiatry Unit, University of Manchester, Manchester, UK.
John McGonigleNeuropsychopharmacology Unit, Centre for Psychiatry, Imperial College London, London, UK.
Csaba OrbanNeuropsychopharmacology Unit, Centre for Psychiatry, Imperial College London, London, UK.
Laurence ReedNeuropsychopharmacology Unit, Centre for Psychiatry, Imperial College London, London, UK.
Eleanor TaylorNeuroscience and Psychiatry Unit, University of Manchester, Manchester, UK.
Remy FlechaisNeuropsychopharmacology Unit, Centre for Psychiatry, Imperial College London, London, UK.
Dana SmithDepartment of Psychiatry, University of Cambridge, Cambridge, UK.
Edward T BullmoreDepartment of Psychiatry, University of Cambridge, Cambridge, UK.
Karen D ErscheDepartment of Psychiatry, University of Cambridge, Cambridge, UK.
John SucklingDepartment of Psychiatry, University of Cambridge, Cambridge, UK.
Rebecca ElliottNeuroscience and Psychiatry Unit, University of Manchester, Manchester, UK.
Bill DeakinNeuroscience and Psychiatry Unit, University of Manchester, Manchester, UK.
Ilan RabinerImanova, Centre for Imaging Sciences, Invicro, London, UK.
Anne Lingford HughesNeuropsychopharmacology Unit, Centre for Psychiatry, Imperial College London, London, UK.
Barbara J SahakianDepartment of Psychiatry, University of Cambridge, Cambridge, UK.
Trevor W RobbinsDepartment of Psychiatry, University of Cambridge, Cambridge, UK.
David J NuttNeuropsychopharmacology Unit, Centre for Psychiatry, Imperial College London, London, UK.
ICCAM Consortium
Imperial College London · GBUniversity of Cambridge · GBUniversity of Manchester · GBInvicro (United Kingdom) · GB

Funding

Medical Research Council G1000018Wellcome Trust
6 · The paper itself

Abstract

Identifying key neural substrates in addiction disorders for targeted drug development remains a major challenge for clinical neuroscience. One emerging target is the opioid system, where substance-dependent populations demonstrate prefrontal opioid dysregulation that predicts impulsivity and relapse. This may suggest that disturbances to the prefrontal opioid system could confer a risk for relapse in addiction due to weakened 'top-down' control over impulsive behaviour. Naltrexone is currently licensed for alcohol dependence and is also used clinically for impulse control disorders. Using a go/no-go (GNG) task, we examined the effects of acute naltrexone on the neural correlates of successful motor impulse control in abstinent alcoholics (AUD), abstinent polysubstance-dependent (poly-SUD) individuals and controls during a randomised double blind placebo controlled fMRI study. In the absence of any differences on GNG task performance, the AUD group showed a significantly greater BOLD response compared to the control group in lateral and medial prefrontal regions during both placebo and naltrexone treatments; effects that were positively correlated with alcohol abstinence. There was also a dissociation in the positive modulating effects of naltrexone in the orbitofrontal cortex (OFC) and anterior insula cortex (AIC) of the AUD and poly-SUD groups respectively. Self-reported trait impulsivity in the poly-SUD group also predicted the effect of naltrexone in the AIC. These results suggest that acute naltrexone differentially amplifies neural responses within two distinct regions of a salience network during successful motor impulse control in abstinent AUD and poly-SUD groups, which are predicted by trait impulsivity in the poly-SUD group.

Indexed as

Alcohol AbstinenceAdultAlcohol DeterrentsAlcoholismDouble-Blind MethodFemaleHumansImpulsive BehaviorMagnetic Resonance ImagingMaleMiddle AgedNaltrexonePsychomotor PerformanceSubstance-Related DisordersYoung AdultAlcohol DeterrentsNaltrexoneaddictionfunctional MRIimpulsivitynaltrexone

Identifiers

PMID30402987
PMCPMC6767584
OpenAlexW2889877579

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.